EMMPRIN expression is associated with metastatic progression in osteosarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Extracellular matrix metalloproteinase inducer (EMMPRIN) is a cell-surface glycoprotein overexpressed in various cancers.
• EMMPRIN drives a metastatic phenotype by stimulating matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF) production.
• Its role in osteosarcoma, a primary bone cancer, requires further investigation.

Purpose of the Study:

• To investigate the expression levels of EMMPRIN in osteosarcoma.
• To elucidate the functional role of EMMPRIN in osteosarcoma progression and metastasis.
• To assess the prognostic significance of EMMPRIN in osteosarcoma patients.

Main Methods:

• EMMPRIN mRNA expression was quantified using RT-PCR in osteosarcoma cell lines and normal osteoblasts.
• Immunohistochemistry was employed to evaluate EMMPRIN expression in patient tumor biopsies.
• siRNA-mediated knockdown of EMMPRIN and in vivo metastasis models were utilized to determine its functional role.

Main Results:

• EMMPRIN mRNA was significantly upregulated in most osteosarcoma cell lines compared to normal cells.
• High EMMPRIN expression in patient samples correlated with shorter metastasis-free survival.
• EMMPRIN knockdown reduced invasion, MMP production, VEGF expression, and lung metastasis in vivo.

Conclusions:

• EMMPRIN significantly contributes to osteosarcoma metastasis by modulating MMP and VEGF.
• EMMPRIN is a potential therapeutic target for inhibiting osteosarcoma progression and metastasis.